Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor combinations in advanced malignancies
NCT02419495Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2015
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in malignant solid neoplasm, melanoma, non-small cell lung carcinoma (NSCLC) and 5 more (16 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events at 3 years. Started Jun 2015; status: terminated.
02
Drugs
selinexor
03
Conditions
malignant solid neoplasmmelanomanon-small cell lung carcinoma (NSCLC)renal cell carcinoma (RCC)ovarian carcinoma
Beyond the preview
Go deeper on NCT02419495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419495.